Trial reportFrontiers in pharmacology2026
Clinical efficacy and mechanistic study of fulvning granules in symptomatic atrial fibrillation: a randomized controlled trial with untargeted metabolomics analysis.
Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Signatures of Atrial Functional Impairment in Paroxysmal Atrial Fibrillation Patients: A CMR Strain-metabolomics Study.Journal of cardiovascular translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most prevalent sustained arrhythmia and a leading cause of morbidity and mortality worldwide. Although antiarrhythmic drugs and catheter ablation have improved AF management, their therapeutic efficacy remains suboptimal. Fulvning Granules (FLN), a regulated hospital preparation officially approved by the Shanghai Drug Administration, have shown promising clinical efficacy in local practice. However, robust high-level clinical evidence is required to validate their benefits and elucidate the underlying mechanisms. Materials and methods: A randomized, double-blind, placebo-controlled trial enrolled 136 symptomatic AF patients, who received either FLN or a placebo for 4 weeks in addition to standard guideline-directed medical therapy (GDMT). The primary endpoint was AF control effectiveness, assessed by 24-h Holter monitoring. Secondary endpoints included palpitation frequency and duration, echocardiographic evaluation of cardiac structure and function, N-terminal pro-B-type natriuretic peptide (NT-pro BNP)levels, Hamilton Anxiety (HAMA) and Depression (HAMD) Scales, and the 36-item Short-Form Health Survey (SF-36) from baseline to week 4. To further validate FLN's efficacy and explore its mechanisms, serum-based metabolic pathway analysis was conducted to investigate the metabolic network associated with FLN treatment of AF. Results: FLN significantly improved AF control compared with placebo (78.57% vs. 54.39%; Conclusion: FLN serves as a safe and effective adjuvant therapy for reducing AF episode frequency and ventricular rate in patients with symptomatic AF. Its mechanism may involve the modulation of cardiac energy metabolism. Clinical Trial Registration: ClinicalTrials.gov, identifier ChiCTR2000036835.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.